MIRA Pharmaceuticals (NASDAQ: MIRA) — Company Overview, News & Financial Data
MIRA Pharmaceuticals develops innovative treatments for various diseases, targeting unmet medical needs in the biotech sector.
MIRA Pharmaceuticals
MIRA Pharmaceuticals (NASDAQ:MIRA) is a dynamic player in the biotechnology sector, focused on developing innovative treatments to address unmet medical needs. The company's operations span from early-stage research to clinical trials, with projects targeting a variety of diseases. MIRA Pharmaceuticals aims to revolutionize patient care through groundbreaking therapies, leveraging the latest scientific discoveries and a highly skilled team. Their portfolio includes potential treatments for rare diseases, chronic conditions, and life-threatening illnesses, underscoring their commitment to improving health outcomes worldwide. With a forward-thinking approach, MIRA Pharmaceuticals strives to lead the way in biopharmaceutical advancements, ensuring better and more accessible treatments for patients around the globe.
Snapshot
Operations
Products and/or services of MIRA Pharmaceuticals
- Development of innovative oncology drugs targeting resistant cancer cells.
- Research on personalized medicine approaches for effective cancer treatments.
- Advanced diagnostic tools for early detection of various cancers.
- Collaboration on biotechnological advancements in gene therapy.
- Manufacturing high-quality, affordable generic medications for widespread health issues.
- Provision of specialized consulting services to healthcare providers on drug management and patient care.
MIRA Pharmaceuticals executive team
- Erez AminovCEO & Chairman
- Andriy MushakChief Financial Officer
- Itzchak AngelChief Scientific Advisor
Latest news about MIRA Pharmaceuticals
MIRA submits Ketamir-2 trial protocol
United StatesMIRA Pharmaceuticals reports positive preclinical data for Mira-55
United StatesMIRA Pharmaceuticals submits Phase 2a protocol for Ketamir-2
United StatesMIRA Pharmaceuticals consolidates global rights for pipeline candidates MIRA-55 and SKNY-1
United States
Key financials
Reported results for MIRA Pharmaceuticals , in USD.
- Market cap
- 24M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.1
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -10.5M | -10.4M | |
| 0 | -8M | -7.9M | |
| 0 | -8.5M | -12M | |
| 0 | -7M | -7.1M |